Please assess the completion status of the following clinical trial:

Trial Title: TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Recipient:~Chronical terminal liver failure, age \> 18 years, first organ transplantation~Donor:~* donor age \> 65 Jahre~* macrovesicular steatosis \> 40% (macroscopy or biopsy)~* BMI \> 30~* sodium \>165 mmol/l~* ICU stay and ventilation \> 7 days~* cold ischemia time \> 13 hours~* AST \> 99 U/l~* ALT \> 105 U/l~* bilirubin \> 3 mg/dl (\> 51 µmol/l)~* application of epinephrine~Exclusion Criteria:~Donor:~• Hepatitis B- or Hepatitis C-infection~Recipient:~* Multi organ transplantation~* high urgency listing~* extrahepatic tumor disease~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus + HTK (Type: EXPERIMENTAL): Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
- HTK (Type: PLACEBO_COMPARATOR): Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).